City of Hope COVID-19 vaccine showed effectiveness in phase 1 trial
On Mar. 10, 2022, a COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to…
-
-
International team created first complete fruit fly cell atlas
On Mar. 9, 2022, Harvard Medical School announced that an international research team had completed an atlas of…
-
Biotechnology | COVID-19 | FDA | Therapeutics
Sorrento announced FDA authorization to proceed with phase 1 study of Intranasal STI-9199 against Covid-19 viruses
On Mar. 2, 2022, Sorrento Therapeutics announced that its Phase I study of intranasal (IN) STI-9199 (COVISHIELDTM IN) has…
-
Landmark Nature Study Provided Long-Sought Mechanistic link between EBV and Multiple Sclerosis
On Jan. 24, 2022, Atara Biotherapeutics, a leader in T-cell immunotherapy, announced that it had leveraged its novel…
-
Illumina and Genetic Alliance Launch $120 million global initiative to increase equity and improve outcomes for families impacted by genetic disease
On Nov. 16, 2021, Illumina and Genetic Alliance announced the creation of the iHope Genetic Health program aimed…
-
Twist Bioscience collaborates with Adicet Bio to accelerate discovery of Gamma Delta T cell cancer therapeutics
On Sept. 13, 2021, Twist Bioscience announced and Adicet Bio announced a collaboration to accelerate the discovery of…
-
Anixa Biosciences and OntoChem entered next stage of development for Covid-19 therapeutic
On Apr. 5, 2021, Anixa Biosciences announced that based on Proof of Concept animal study results, it was…
-
FDA issued an EUA to the Twist Bioscience for their SARS-CoV-2 NGS assay.
On Mar. 26, 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) to…
-
Cepheid received Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test
On Mar. 21, 2021, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
-
TGen study predicted changing Lyme disease habitat across the West Coast
On Mar. 16, 2021, TGen announced a study that suggested ecosystems suitable for harboring ticks that carry debilitating…
-
ImmunityBio announced positive interim phase I safety data of hAd5 T-cell COVID-19 vaccine candidate
On Mar. 15, 2021, ImmunityBio announced it had met the safety requirements for the first 12 participants in…
-
Rigel announced completion of patient enrollment for phase 2 trial of fostamatinib in hospitalized COVID-19 patients
On Mar. 11, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical trial to…
-
ImmunityBio announced novel ACE2 decoy COVID-19 therapeutic that showed high binding to SARS-CoV-2 variants
On Mar. 11, 2021, ImmunityBio announced it was developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize…
-
The U.S. Department of Defense identified more troops to help administer COVID-19 vaccine
On Mar. 10, 2021, the U.S. Department of Defense (DOD) announced that it had identified additional personnel authorized…
-
AXIM Biotechnologies successfully completed point-of-care clinical trials on rapid COVID-19 antibody test
On Mar. 8, 2021, AXIM Biotechnologies announced that it had successfully completed point-of-care clinical trials on its much…
-
ImmunityBio and NantKwest began dosing participants in global trials for novel COVID-19 vaccine
On Mar. 8, 2021, ImmunityBio and NantKwest announced that the first cohorts of their South Africa and U.S….
-
MediciNova announced it had discontinued development of a SARS-CoV-2 vaccine for COVID-19
On Mar. 3, 2021, MediciNova announced an update on the development of a SARS-CoV-2 vaccine for COVID-19. MediciNova…
-
Vaxart announced publication that showed potential clinical and economic value of a Norovirus vaccine
On Jan. 27, 2021, Vaxart announced that health care economic findings published in the American Journal of Preventative…
-
Vaxart announced additional preclinical COVID-19 oral vaccine data and publication
On Jan. 26, 2021, Vaxart announced additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a…
-
Gilead announced long-acting HIV-1 capsid inhibitor, lenacapavir, achieved primary endpoint in phase 2/3 study
On Nov. 18, 2020, Gilead Sciences announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s…
-
Stanford developed CRISPR ‘lab on a chip’ for detecting COVID-19
On Nov. 4, 2020, using the cutting-edge genetic editing technique known as CRISP ‘lab on a chip’ technology,…
-
UC Berkeley launched pop-up lab to monitor Bay Area sewage for COVID-19
On Oct. 29, 2020, the University of California, Berkeley (UC Berkeley) announced that it had launched a new…
-
Biotechnology | Chemistry | CRISPR | Genomics | Therapeutics
Nobel Prize in Chemistry for 2020 awarded to Emmanuelle Charpentier and Jennifer A Doudna “for the development of a method for genome editing”
On Oct. 7, 2020, the Nobel Prize in Chemistry 2020 was awarded to Drs. Emmanuelle Charpentier and Jennifer…
-
Lilly and Amgen announced manufacturing collaboration for COVID-19 antibody therapies
On Sept. 17, 2020, Eli Lilly and Amgen announced a global antibody manufacturing collaboration to significantly increase the supply…
-
Scientists revealed structural details of spike protein used in leading COVID-19 vaccine
On Aug. 7, 2020, scientists at Scripps Research announced they had obtained high-resolution, atomic-scale details of the structure…
-
Members of the COVID R&D alliance and quantum leap healthcare collaborative enrolled first patients in I-SPY COVID trial
On Aug. 3, 2020, members of the COVID R&D Alliance AbbVie, Amgen and Takeda Pharma announced the first…
-
From lung scarring to heart damage, COVID-19 may leave lingering marks
On Jul. 8, 2020, scientists at the UC Berkeley-UCSF Joint Medical Program reported that for some individuals with…
-
Mateon selected by IBM Watson Health for use of IBM Clinical Development Solution to support clinical COVID-19 vaccine candidates
On Jun. 24, 2020, Oncotelic, a wholly owned subsidiary of Mateon Therapeutics, announced that IBM has granted access…
-
ViralClear published comparative in vitro data on merimepodib and remdesivir activity against COVID-19 novel Coronavirus in F1000 research
On Apr. 30, 2020, BioSig Technologies announced that an article titled, ‘The IMPDH inhibitor merimepodib has similar antiviral…
-
NIH clinical trial shows remdesivir accelerated recovery from advanced COVID-19
On Apr. 29, 2020, the National Institutes of Health (NIH) announced that hospitalized patients with advanced COVID-19 and…
